News and Trends 4 Apr 2023
BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal
BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets globally, excluding mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. With this collaboration, ADCs will become an additional drug class in […]